A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
REGULATORY
Nichi-Iko to Get Business Suspension Order on March 3
Toyama prefectural authorities and the Ministry of Health, Labor and Welfare (MHLW) are in the final stages of adjustments to issue a business suspension order to generic major Nichi-Iko Pharmaceutical on March 3 over a raft of voluntary recalls attributable…
To read the full story
Related Article
- Nichi-Iko Suspended from JGA Membership
March 10, 2021
- Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
- Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
- Nichi-Iko Likely to Face Biz Suspension Order over Spate of Recalls
February 25, 2021
- Administrative Penalty on Nichi-Iko Possible by March-End over Recalls
January 15, 2021
- Nichi-Iko Announces Yet Another Recall, 38 Products Added to Bring Total to 75
January 14, 2021
- Nichi-Iko Stops Supply of Clinoril Due to Dissolution Issue
December 23, 2020
- Nichi-Iko Recalls 4 More Products Including Theophylline due to Deviations from Approved Specifications
December 11, 2020
- Some Hospitals Shun New Nichi-Iko Generics after Massive Recalls, President Reveals
November 13, 2020
- Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals
November 11, 2020
- Nichi-Iko to Revamp Quality Control System after Massive Recalls by Leveraging Teva Takeda Plant
August 28, 2020
- Nichi-Iko Launches Another Recall, Now Pulling 8 More APIs/9 Products
May 19, 2020
- Nichi-Iko Recalling 12 APIs/15 Products over Quality, Compliance Issues
April 9, 2020
REGULATORY
- Optimal Use Guidelines Issued for Vyepti; Updates for Leqembi, Kisunla, Keytruda
November 13, 2026
- New Radiopharma Action Plan Urges Domestic CDMO Development: Draft
November 13, 2026
- Chuikyo OKs Tougher CEA Price Cuts for Drugs Tagged “Cost Increase”
November 12, 2026
- Chuikyo Weighs “Agile Response” to MFN as Providers Question Drug Lag, Loss Impact
November 12, 2026
- Japan to List Eylea Biosimilars from SamChunDang, Celltrion on Nov. 13
November 12, 2026
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…